{"ok":true,"entity":{"id":"recursion-pharmaceuticals","name":"Recursion Pharmaceuticals","entityType":"company","officialName":"Recursion Pharmaceuticals, Inc.","canonicalName":"Recursion Pharmaceuticals","displayName":"Recursion Pharmaceuticals","category":"AI創薬のTechBio企業","shortDescription":"Recursion Pharmaceuticals, Inc.（Nasdaq: RXRX）は、ユタ州ソルトレイクシティに本社を置き、AIを活用した創薬プラットフォーム「Recursion OS」を運営する臨床段階のTechBio企業。2026年第2四半期の売上高は770万米ドル、純損失は1億3,100万米ドル。2026年10月にSanofiが最初の開発候補をオプション行使し、同月に約2億米ドルの株式公募の価格決定を発表した（2026年10月時点）。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.recursion.com/","updatedAt":"2026-10-22T11:50:32.298Z","secondaryClusters":[],"alias":["Recursion"],"searchKeywords":["Recursion","リカージョン","AI創薬","TechBio","Recursion OS","REC-4881","RXRX","drug discovery"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}